What type of study is this?

This is a In Vitro Study study (also classified as: Observational).

August 21, 2025Open Access

Figure 1 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models

Key Points

Co-targeting Bcl-xL and Mcl-1 showed significant synergistic effects in treating AR-V7 positive models of CRPC, enhancing cell response.
The highest synergy score from pairing S63845 with BH3-mimetic drugs indicates greater effectiveness in LNCaP95 and VCaP-CR models.
Observational data analysis utilized patient mRNA sequencing to profile expression levels of AR, BCL2, Bcl-xL, and MCL1 in mCRPC cases.
The findings may enable new treatment strategies against AR-V7 expressing CRPC, warranting further clinical exploration.

Abstract

Identification of Synergistic BH3-mimetic–based combinations in LNCaP95 and VCaP-CR Cells. A, Correlation plot depicting DBSumNeg (synergy score) for drugs that pair well with S63845 across LNCaP95 and VCaP-CR lines. B, All pairings of BH3 mimetics ranked by average DBSumNeg across LNCaP95 and VCaP-CR lines. C to F, Example drug screen data from A-1331852 paired with S63845 in VCaP-CR (C and D) and LNCaP95 (E and F) cells using CellTiter-Glo to measure response. Cell viability (C and E) and Bliss synergy were calculated for each point. Z-plots depict Bliss synergy score at each concentration (D and F). G, Patient mRNA sequencing data from the SU2C 2019 cohort of patients with mCRPC reveals the expression of AR, BCL2, Bcl-xL, and MCL1. Cohort expression was displayed utilizing GraphPad Prism 10, and data are expressed as fragments per kilobase of transcript per million mapped reads (FPKM).

Figure 1 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models

Key Points

Abstract

Cite This Study

Also Consider

Also Consider